AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) ~~Kit~~ A kit for screening molecules ~~with~~ having an anti-prion activity, ~~characterized in that it comprises in combination~~ comprising:

a yeast of phenotype [*PSI+*][[,]];

an antibiogram; and

a prion curing agent in a sub-effective ~~doses,~~ dose, ~~said~~ wherein the yeast ~~having~~ has the *adel-14* allele of the *ADE1* gene ~~as well as~~ and an inactivated *ERG6* gene.

2. (Currently Amended) ~~Kit according to~~ The kit of claim 1, ~~characterized in that~~ wherein the yeast is *Saccharomyces cerevisiae*.

3. (Currently Amended) ~~Kit according to claim 1 or 2, characterized in that~~ The kit of claim 1, wherein the prion curing agent is guanidium chloride.

4. (Currently Amended) ~~Method~~ A method for screening molecules ~~with~~ having anti-prion activity, ~~characterized in that it uses a [*PSI+*] phenotype yeast having the *adel-14* allele of the *ADE1* gene as well as an inactivated *ERG6* gene and comprises the following stages:~~ the method comprising:

a. ~~production of~~ producing *in vitro* a lawn of cells ~~*in vitro*~~ on a medium ~~complemented with~~ containing a sub-effective dose of a prion curing agent[[,]];

b. ~~deposition of the compounds to be tested~~ contacting the cells with a test compound according to the antibiogram method[[,]];

c. ~~incubation~~ incubating the cells for approximately 2-4 days at approximately 20-25°C[[,]]; and [[,]]

d. ~~analysis of~~ evaluating the staining of the cell colonies[[.]], wherein the cells comprise yeasts of [*PSI*+] phenotype having the *adel-14* allele of the *ADE1* gene and an inactivated *ERG6* gene.

5. (Currently Amended) ~~Screening~~ The screening method ~~according to~~ of claim 4, ~~characterized in that~~ wherein the yeast is *Saccharomyces cerevisiae*.

6. (Currently Amended) ~~Screening~~ The screening method ~~according to any one of claims 4 or 5, characterized in that~~ of claim 4, wherein the curing agent ~~of Stage a.~~ is guanidium chloride.

7. (Currently Amended) ~~Screening~~ The screening method ~~according to any one of claims 4 to 6, characterized in that it moreover comprises the following stages:~~ of claim 4 further comprising:

e. ~~incubation~~ incubating for approximately 2-4 days at approximately 2-6°C[[,]]; and/or[[,]]

f. carrying out a secondary screening test.

8. (Currently Amended) ~~Screening~~ The screening method ~~according to~~ of claim 7, ~~characterized in that~~ wherein the secondary screening test ~~comprises the following stages:~~ comprises:

[[-]] ~~construction of~~ constructing a strain of yeast in which the *ADE2* gene is under the control of the *DAL5* gene promoter;

[[-]] ~~carrying out Stages a. to e. of the methods according to claims 4 and 7.~~

producing *in vitro* a lawn of cells on a medium containing a sub-effective dose of a prion curing agent;

contacting the cells with a test compound according to the antibiogram method;

incubating the cells for approximately 2-4 days at approximately 20-25°C;

evaluating the staining of the cell colonies; and

incubating for approximately 2-4 days at approximately 2-6°C.

9. (Currently Amended) ~~Compound~~ A medicament comprising the compound of formula (II): ~~in which:~~



(II)

wherein R' represents an H, NH_2, $NH-(CH_2)_3-N(CH_3)_2$, $NH-CH(CH_3)-(CH_2)_3-$ or $N(CH_2-CH_3)_2$ group,

X represents F, Cl, or CF_3,

p and n, identical or different, are equal to 0, 1 or 2 ~~for use as a medicament~~.

10. (Currently Amended) ~~Compound according to~~ The medicament of claim 9 comprising the compound of formula (II): ~~in which:~~



(II)

wherein R' represents an NH_2 group,

X represents F, Cl, or CF_3,

p and n, identical or different, are equal to 0, 1 or 2[[,]].

~~for use as a medicament.~~

11. (Currently Amended) ~~Use of~~ A method for treating neurodegenerative diseases involving protein aggregates, the method comprising:

administering the compound of formula (I)



(I)

~~in which~~ wherein R' is an H, NH_2, or NHR^2 group, ~~where~~ wherein R^2 is an alkyl or alkylaminoalkyl chain with 1 to 10 carbon atoms, branched or unbranched,

X represents F, Cl, Br, I, CF_3, SCH_3, OCH_3, OH, NO_2, $COCH_3$, $CONH_2$, COOH, or $COOR^3$, where R^3 is an alkyl group with 1 to 4 carbon atoms,

p and n, identical or different, are equal to 0, 1 or 2,

q is equal to 0 or 1[[,]].

~~in order to obtain a medicament intended for treating neurodegenerative diseases involving protein aggregates.~~

12. (Currently Amended) ~~Use of~~ A method for treating neurodegenerative diseases involving protein aggregates, the method comprising:

administering the compound of formula (III) ~~in which:~~



(III)

wherein R' represents an H, NH_2, $NH-(CH_2)_3-N(CH_3)_2$, $NH-CH(CH_3)-$ or $(CH_2)_3-N(CH_2-CH_3)_2$ group,

X represents F, Cl, or CF_3,

p and n, identical or different, are equal to 0, 1 or 2.

~~in order to obtain a medicament intended for treating neurodegenerative diseases involving protein aggregates.~~

13. (Currently Amended) ~~Use of~~ A method for treating neurodegenerative diseases involving protein aggregates, the method comprising:

administering the compound of formula (II) ~~in which:~~



(II)

wherein R' represents an H, NH_2, $NH-(CH_2)_3-N(CH_3)_2$, $NH-CH(CH_3)-(CH_2)_3-$ or $N(CH_2-CH_3)_2$ group,

X represents F, Cl, or CF_3,

p and n, identical or different, are equal to 0, 1 or 2 [[,]].

~~in order to obtain a medicament intended for treating neurodegenerative diseases involving protein aggregates.~~

14. (Currently Amended) ~~Use of~~ The method of claim 13

~~the compound of formula (II) in which:~~



~~(II)~~

wherein R' represents an NH_2 group,

X represents F, Cl, or CF_3,

p and n, identical or different, are equal to 0, 1 or 2[[,]].

~~in order to obtain a medicament intended for treating neurodegenerative diseases involving protein aggregates.~~

15. (Currently Amended) ~~Use according to claims 11 to 15, characterized in that~~ The method of claim 11, wherein the neurodegenerative diseases ~~are the~~ include: spongiform encephalopathies, Alzheimer's disease, and Huntington's disease.

16. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical composition comprising:

a therapeutically effective quantity of at least one compound of formula (II) ~~in which:~~



(II)

wherein R' represents an H, NH_2, $NH-(CH_2)_3-N(CH_3)_2$, $NH-CH(CH_3)-$ or $(CH_2)_3-N(CH_2-CH_3)_2$ group,

X represents F, Cl, or CF_3,

p and n, identical or different, are equal to 0, 1 or 2[[.]].

in combination with at least one pharmaceutically acceptable vehicle.

17. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition of claim 16 ~~comprising a therapeutically effective quantity of at least one compound of formula (II) in which:~~



~~(II)~~

wherein R' represents an NH_2 group,

X represents F, Cl, or CF_3,

p and n, identical or different, are equal to 0, 1 or 2 [[,]].

~~in combination with at least one pharmaceutically acceptable vehicle.~~